A PLSP video summary of the HIMALAYA study: comparing immunotherapy options for unresectable hepatocellular carcinoma

This animated video article presents a breakdown of the HIMALAYA Phase III clinical study, which compared two immunotherapy treatments against sorafenib in patients with unresectable hepatocellular carcinoma.

The content of this animated video article is based on the manuscript, “Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer)”, published in Future Oncology.

Click here or on the link below to read the Plain Language Summary of Publication (PLSP).

Durvalumab is also an approved treatment for adults with advanced biliary tract cancers (BTC) in combination with chemotherapy by government organizations in Europe, the United States and several other countries. Click here or on the link below to learn about the Phase III TOPAZ-1 study, which investigated durvalumab plus chemotherapy to treat patients with advanced BTCs.